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Studies concerning the local and systemic use of 
ozonotherapy confirm its effectiveness compared to other 
physical methods. Therapeutic ozone concentrations (in 
a physiological solution from 1 mg/l to 6 mg/l, on aver-
age 3-4 mg/l with a single dose of 1.2-1.6 mg) activate 
the immunomodulatory function of the body. When 
administering ozone on the membranes of phagocytic 
cells (leukocytes, monocytes, macrophages) hydrophilic 
compounds are adsorbed. Ozonides stimulate cytokines, 
which, in their turn, promote activation of cellular and 
humoral immunity, and increases the rate of body’s 
nonspecific protection system.
However, the effect of ozone on pyoinflammatory state 
of the soft tissues, depending on the administered dose and 
severity of the process [1-3,8,10], have not been adequately 
evaluated in patients with diabetes mellitus.
Therefore, the need emerged to find out the cellular 
mechanisms of wound healing regulation impairment, 
disease course characteristics and treatment superiority 
with the use of ozonotherapy during pyoinflammatory 
complications of soft tissues secondary to diabetes mellitus. 
Moreover, our study is significant, as from theoretical, so 
from the practical view [4-7,9,10].
The aim of our study is to improve management of pyo-
inflammatory processes in patients with diabetes mellitus 
with individually selected dose of ozonotherapy.
Material and methods. In total, 124 patients with 
diabetes and pyoinflammatory complications were 
enrolled in the study. Depending on the severity of the 
diabetes course, patients were divided into two groups: 
first group consisted of patients with severe stage – 76 
(61.2%) and second group consisted of patients with 
moderate stage – 48 (38.7%). 
Enrolled patients were also divided into two groups de-
pending on treatment option. The main group - 53 (42.7%) 
was treated with individually selected dose of ozone ther-
apy, while control group - 71 (57.2%) received only con-
ventional treatment. Most patients in the main group - 76 
(61.2%) had severe conditions, including diabetic gangrene 
in the distal regions of the foot - 17 (13.7%), phlegmone of 
the foot - 25 (20.16%), phlegmone of the ankle - 5 (4.03%), 
phlegmone of the perineum - 1 (0.8%), as well as isolated 
cases of phlegmone of the anterior abdominal wall (0.8%) 
and thigh (0.8%), purulent omphalitis (0.8%) and purulent 
wounds of the forearm (0.8%).
Pyoinflammatory lesions of the right lower limb in the 
study population were observed in 71 (57.2%) patients, and 
lesions of the left limb – in 53 (42.7%) patients.
During the treatment period, conservative therapeu-
tic procedures and various surgical interventions were 
performed in most study participants: the primary sur-
gical treatment of the wound - in 33 (26.6%) patients; 
exarticulation of the fingers of the lower extremities in 37 
(29.8%) patients (including exarticulation of the Ist finger 
in 11 (8.9%) cases, ІІnd finger – in 10 (8.1%) cases, ІІІrd 
finger – in 5 (4.0%) cases, IVth finger – in 4 (3.2%) cases, 
Vth finger – in 7 (5.6%) cases); disclosure and drainage of 
soft tissues ulcers in 30 (24.2%) patients. 
Amputation of the lower extremities at the level of 
the lower third of the thigh was performed in 15 (12.1%) 
patients; reamputation of the lower limb at the level of 
the lower third of the thigh was performed in one (0.8%) 
patients; foot amputation according to the Chopart method 
was performed in one (0.8%) patient; autodermoplasty 
was performed in 7 (5.6%) patients after the elimination 
of purulent-inflammatory processes of soft tissues on large 
and sluggishly granulating wounds.
Conservative treatment included the following 
medications: infusion therapy (5% glucose solution, 
Ringer-Locke’s solution, 0.9% sodium chloride solu-
tion, Reosorbilact and others), vasoactive medications 
(Trental, Vasaprostan), nicotinic acid and medications 
containing nicotinic acid: Teonicol, Complamine, xan-
thinol nicotinate, reocorrectors (Rheopolyglukin), an-
ticoagulants and antiagregants (Heparin, Fraxiparine, 
Aspirin, a wide range of antibiotics), antispasmodic 
medications (No-Spa, Spasmalgon, Platyphylline), 
Vitamins A, C, E, of B group, biological stimulants, 
anabolic steroid medications (Retabolil, Nerobol), 
antagonists of calcium ions (Verapamil, Cinnarizinum, 
Corinfar), cocarboxylase, ATP, desensitizing medi-
cations (Dimedrol solution, Suprastin, Loratadine), 
diuretics (Lasix, Furosemide), anti-inflammatory 
medications (Nimesil, Diclofenac, Naklofen), cardio-
logical medications, medications for lipid metabolism 
correction – lipoic acid, Berlithion.
All patients from the main group received individually 
selected dose of ozone therapy in addition with traditional 
treatment and surgical interventions. Individual doses of 
ozone was determined using lymphocytotoxic test and 
was delivered by catheter into the ulnar vein (Table 1) for 
6 day-period.
Ozone was delivered by automated ozone device “Bo-
son” produced by the Scientific and Production Enterprise 
“Econika” in Odessa, Ukraine. The technological process of 
manufacturing ozone-containing saline solution was carried 
out in accordance with the standard method of preparation 
of ozone-containing saline solution for parenteral adminis-
tration based on the methodological recommendations of 
the Ministry of Health of Ukraine.
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The criteria for patient’s discharge from the clinic were 
the following: cessation of the spread of purulent-necrotic 
focus, the development of granulation tissue in the wound 
and the onset of marginal epithelization.
Statistical processing of the material was carried 
out using methods of variation statistics with standard 
techniques.
Results and their discussion. In medicine ozone is used 
as an ozone-oxygen mixture for local and systemic use. The 
selective effect of ozone having double and triple bonds on 
compounds is already determined. They include proteins, 
amino acids and unsaturated fatty acids that form part of the 
plasma lipoprotein complexes and the lipid biological layer of 
cell membranes. Reactions with these compounds make the 
basis of biological effects of ozonotherapy and have patho-
genetic significance in various diseases.
The concentrations of ozonation are proposed by various 
authors: they are different and depend on many factors. [2,4,8].
It is appropriate to use an ozone-oxygen mixture with a 
concentration of 0.2 to 80 mg of ozone per liter of oxygen, 
since different types of metabolic reactions arise in differ-
ent pathologies.
To achieve the overall metabolic effect, a technique, 
which gives good clinical results and eliminates the com-
plications, is used; the concentration of ozone at the outlet 
of the ozonator is assigned at a rate of 20 μg per 1 kg body 
weight of the patient.
Selecting individual dose of ozone is very important 
for the patients with different types of metabolic reactions 
in various pathologies.
In our study participants with diabetes mellitus pre-
dominantly had severe inflammatory complications., For 
all study subjects the concentration of ozone was selected 
individually by the lymphocytotoxic test [8]; the ultimate 
concentration of ozone in vitro was 40 mg/l (Table 1).
The dose of ozone in the amount of 55 mg/l led to 
the destruction of lymphocytes and was ineffective for 
therapeutically use. Our study showed that patients who 
received ozone therapy in addition with traditional or 
surgical treatment had less pain complaints than sub-
jects from the control group. In addition to pain relief, 
regression of edema, infiltration and hyperemia around 
the wound were observed in these patients. Moreover, 
after 2-3 procedures body temperature decreased and 
sleep and appetite normalized.
Interestingly, for the subjects from the control group all 
above-mentioned features normalized only on the 12-14th 
day of inpatient treatment. 
 Difference was observed also in the appearance of 
granulations between main and control groups: granula-
tion appeared on average after 3-9th day of treatment in the 
main group and after 10-17th days in the control group In 
44 (83%) patients from the main group the wound process 
was not complicated by the formation of necrotic changes 
in tissues after surgery. On the second day from surgery, 
in most cases from the main group, there was no need of 
narcotic anesthetic medications.
The addition of ozone therapy positively affected 
the duration of the hospital stay. Patients from the main 
group stayed in the hospital on average 9-12 days, while 
prolonged average stay was observed in patients from the 
control group -15-19 days.
 Blood glucose levels were evaluated at baseline and 
on 3rd, 6th and 14th day after surgery in both study groups. 
At baseline the glucose levels did not differ between two 
groups. After 6 days of treatment glucose values in the 
main group was decreased and clinically significant dif-
ference was observed between the groups Although we 
have to admit that after 14 days of treatment the glucose 
levels decreased in both groups and reached almost similar 
values (Table 2).
The value of the leukocyte index of intoxication in norm 
equals to 1.04±0.5. The dynamics of the leukocyte index 
of intoxication in study population was as follows: In the 
main group 3.6±0.3, 2.8±0.2 and 1.8±0.1 - at the time of 
admission, after 6 and 14 days of treatment, respectively. 
In the control group leukocyte index of intoxication was 
3.6±0.2, 3.7±0.2 and 2.6±0.2 - at the time of admission, 
after 6 and 14 days of treatment, respectively. 
The baseline and after treatment results of other general 




1 stage of severity 2 stage of severity 3 stage of severity
control main control c main control c main
10 mg/l 42 34 34 32 41 47
20 mg/l 42 38 34 28 41 34
40 mg/l 42 31 34 21 41 55
Table 2. Dynamics of blood glucose changes during the treatment process
Group of patients
Glucose levels, mmol/l
3rd day 6th day 14th day
Main group (n=53) 10.4 ±4.5 8.4 ±1.3 8.2 ±1.2
Control group (n=71) 10.8 ±4.2 11.6 ±1.5 8.8 ± 2.2
 
GEORGIAN MEDICAL NEWS  
No 2 (275) 2018
© GMN 93 
and biochemical blood tests did not differ significantly 
between the main and control groups.
Conclusions. Our study showed that the dose of ozone 
should be selected individually for each patient according 
to the lymphocytotoxic test and depending on the severity 
of the course of diabetes complication. 
 In patients who underwent ozone therapy with individu-
ally selected dose, the proliferation of purulent necrotic focus, 
development of the granulation tissue in the wound and the 
onset of border epithelization occurred faster then those who 
received only traditional treatment. Moreover, their period of 
hospital stay was 3 days shorter compared to the control group. 
In adittion, glucose levels and leukocyte index of intoxication 
was markedely lower after ozone therapy. 
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SUMMARY
TREATMENT OF PYOINFLAMMATORY COMPLICATIONS 
WITH INDIVIDUALLY SELECTED OZONE DOSE IN PATIENTS WITH DIABETES
Karatieieva S., Makarova O., Yurkiv O., Semenenko S., Berezova M.
Higher State Educational Institution of Ukraine “Bukovinian State Medical University”, Chernivtsi, Ukraine
The severity of purulent-inflammatory process in 
patients with diabetes mellitus is determined by lym-
phocytotoxic test. The test shows that application of 
intravenous ozone therapy with individually selected 
ozone dose significantly decreases the spread of necrotic 
suppurative focus already on the third day of treatment. 
Granulation tissue and marginal epithelization in the 
wound develops on the 6-8th day of hospitalization; 
normalization of glycemic levels shorten of the period 
of the hospital stay up to 3-5 days, compared to the 
control group.
Keywords: pyoinflammatory complications, diabetes 
mellitus, ozonotherapy.
РЕЗЮМЕ
ЛЕЧЕНИЕ ГНОЙНО-ВОСПАЛИТЕЛЬНЫХ ОСЛОЖНЕНИЙ 
У БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ С ИНДИВИДУАЛЬНЫМ ПОДБОРОМ ДОЗЫ ОЗОНА
Каратеева С.Ю., Макарова О.В., Юркив О.И., Семененко С.Б., Березова М.С.
Высшее государственное учебное заведение Украины 
Буковинский государственный медицинский университет, Черновцы, Украина 
Применение у больных сахарным диабетом с гнойно-вос-
палительными осложнениями в лечении, внутривенной 
озонотерапии с индивидуальным подбором дозы озона, в 
зависимости от тяжести течения гнойно-воспалительного 
процесса по лимфоцитотоксическому тесту, значительно 
способствует снижению распространения гнойно-не-
кротического очага уже на третьи сутки. Развитие в ране 
грануляционной ткани и краевой эпителизации проис-
ходит на 6-8 сутки стационарного пребывания больных, 
а также снижение показателей уровня сахара в крови, 
сокращению срока стационарного пребывания больных 





Saqriani diabetiT da Cirqovan-anTebiTi 
garTulebebiT avadmyofebis mkurnalobaSi 
ozonoTerapiis gamoyeneba ozonis individu-
alurad SerCeuli doziT da Cirqovan-an-
TebiTi procesis simZimis gaTvaliswinebiT 
limfocitotoqsikuri testis meSveobiT 
uzrunvelyofs Cirqovan nekrozuli keris 
gavrcelebis Semcirebas. Wrilobis gran-
ulaciuri qsovilis da napirebis epiTe-
lizaciis ganviTareba xdeba avadmyofis 
stacionarSi yofnis me-6-8 dRes. aseve mim-
dinareobs sisxlSi Saqris maCveneblis da 
avadmyofebis stacionarSi yofnis peri-
odis Semcireba 3-5 dRe-RamiT SedarebiT im 
avadmyofebTan, romlebsac ar CautardaT 
ozonoTerapia.
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s. karateeva, o. makarova, o. iurkivi, s. semenenko, m. berezova
ukrainis saxelmwifo umaRlesi ganaTlebis dawesebuleba 
"bukovinis saxelmwifo samedicino unoversiteti", Cernovci, ukraina
РОЛЬ НЕКОТОРЫХ ВАЗОАКТИВНЫХ ПЕПТИДОВ В ПАТОГЕНЕЗЕ 
РАННИХ ФОРМ РОЗАЦЕА И СОСТОЯНИЕ СИСТЕМЫ ГЕМОСТАЗА
Цискаришвили Ц.И., Кацитадзе А.Г., Цискаришвили Н.В., Цискаришвили Н.И.
Тбилисский государственный медицинский университет, департамент дерматовенерологии, Грузия
Розацеа представляет собой хроническое кожное 
заболевание неизвестной этиологии, поражающее 
преимущественно центральную область кожи лица 
(щеки, подбородок, нос и лоб), характризуется 
периодами ремиссий и обострений. Актуальность 
проблемы розацеа очевидна в силу широкого рас-
пространения, отсутствия четкого представления об 
этиологии, резистентности к терапии, а также нали-
чия не только медицинских, но и косметологических 
аспектов, которые усугубляются психоэмоциоаналь-
ными расстройствами [1].
Большинство исследователей существенную роль 
в патогенезе отводят сосудистым нарушениям [2,3,5]. 
Патология капилляров кожи связана с несколькими 
факторами, которых объединяет один результат 
- стойкое расширение сосудов кожи и в последу-
ющем стаз крови [5], что клинически проявляется 
эритемой и телеангиэктазиями. В последнее время 
в патогенезе розацеа все чаще обсуждается значение 
вазоактивных пептидов желудочно-кишечного тракта 
(пентагастрин, вазоактивный кишечный пептид - 
VIP) и медиаторных веществ, таких как эндорфины, 
брадикинин, серотонин, гистамин и субстианция 
Р [4]. Ключевая роль в механизме вазодилатации, 
увеличения проницаемости сосудов, развития вос-
паления, ангиогенеза принадлежит сосудистому 
эндотелиальному фактору роста (vascular endothelial 
growth factor - VEGF). VEGF, является одним из 
членов семейства структурно близких между со-
бой белков - лигандов для семейства рецепторов 
одноименного цитокина, который связывается с 
двумя близкими по строению мембранными тиро-
зинкиназными рецепторами (VEGF-1 и VGTF-2) 
и активирует их, способствуя повышению уровня 
IL-8, играющего значительную роль в развитии вос-
паления [7]. VEGF синтезируется активированными 
кератиноцитами в результате воздействия различных 
факторов, в частности, ультрафиолетовое облучение 
провоцирует  выработку цитокинов IL-1 и TNF-α, 
которые стимулируют кератиноциты к синтезу VEGF 
[2,9]. Последний влечет за собой продукцию энзимов 
(матриксных металлопротеаз), вызывая деградацию 
волокон дермы, поддерживающих кровеносные со-
суды, провоцируя атонию стенок сосудов и повышая 
их хрупкость [6]. Полагают, что именно этот фактор 
имеет этиологическое значение при розацеа. Проведено 
изучение экспрессии VEGF у больных розацеа, выяв-
лена повышенная экспрессия VEGF и его рецепторов 
клетками эпидермиса. В биоптатах кожи обнаружены 
периваскулярные и перифолликулярные лимфогисто-
цитарные инфильтраты и расширенные кровеносные 
сосуды. Данные, касающиеся состояния свертывающей 
системы у больных розацеа, свидетельствуют о на-
личии сдвига функциональной активности гемостаза 
